- Home
- SAFT vs NVAX Comparison
SAFT vs NVAX Comparison
Compare SAFT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAFT | NVAX |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | SAFT | NVAX |
|---|---|---|
| Price | $75.90 | $9.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.78 |
| AVG Volume (30 Days) | 60.7K | ★ 5.4M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ 15.78 | N/A |
| EPS | ★ 5.87 | 2.07 |
| Revenue | ★ $1,231,116,000.00 | $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.94 | ★ $4.71 |
| Revenue Growth | 12.77 | ★ 20.27 |
| 52 Week Low | $67.04 | $5.01 |
| 52 Week High | $84.20 | $10.65 |
Technical Indicators
Market Signals| Indicator | SAFT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 72.34 |
| Support Level | $74.47 | $7.73 |
| Resistance Level | $76.44 | $8.81 |
| Average True Range (ATR) | 1.62 | 0.60 |
| MACD | -0.18 | 0.24 |
| Stochastic Oscillator | 36.20 | 87.09 |
Price Performance
Historical ComparisonAbout SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.